Differential production of insulin-like growth factor-binding proteins in liver fibrosis progression
Por:
Martinez-Castillo, Moises, Rosique-Oramas, Dorothy, Medina-Avila, Zaira, Luis Perez-Hernandez, Jose, Higuera-De la Tijera, Fatima, Santana-Vargas, Daniel, Esteban Montalvo-Jave, Eduardo, Sanchez-Avila, Francico, TORRE, ALDO, KERSHENOBICH, DAVID, Gutierrez-Reyes, Gabriela
Publicada:
1 jun 2020
Resumen:
Noninvasive methods for liver disease diagnoses offer great advantages
over biopsy, but they cannot be utilized in all cases. Therefore,
specific indicators for chronic liver disease management are necessary.
The aim was to assess the production of insulin-like growth
factor-binding proteins (IGFBPs) 1-7 and their correlation with the
different stages of fibrosis in chronic hepatitis C (CHC). A
prospective, cross-sectional, multicenter study was conducted. CHC
patients were categorized by FibroTest (R) and/or FibroScan (R). Serum
concentrations of IGFBPs 1-7 were determined through multiple suspension
arrangement array technology. Significant differences were validated by
the Kruskal-Wallis and Mann-Whitney U tests. Logistic regression models
were performed to assess the association between the IGFBPs and fibrosis
stages. The association was determined utilizing odds ratios (ORs), and
receiver operating characteristic (ROC) curves were constructed to
distinguish the IGFBPs in relation to the diagnosis of fibrosis. IGFBP-1
and IGFBP-7 concentrations were higher in CHC than in the healthy
individuals, whereas IGFBP-3, IGFBP-5, and IGFBP-6 were downregulated in
the patients. An apparent increase of all the IGFBPs was found at
fibrosis stage F4, but with different regulations. IGFBP-2, -4, -6, and
-7 had the best OR, showing the relation to fibrosis progression. The
ROC curves showed that IGFBP-7 was the only protein that distinguished
F1 from F3 and F2 from F3. IGFBPs participate in liver fibrosis
progression and could be employed as circulating novel protein panels
for diagnosis and as possible therapeutic targets in liver fibrosis
progression.
Filiaciones:
Natl Autonomous Univ Mexico UNAM, Gen Hosp Mexico, Sch Med, Unit Expt Med,Liver,Pancreas & Motil Lab HIPAM, Mexico City, DF, Mexico
Gen Hosp Mexico Dr Eduardo Liceaga, Mexico City, DF, Mexico
Natl Inst Med Sci & Nutr Salvador Zubiran, Mexico City, DF, Mexico
|